All-trans-retinoic acid in acute promyelocytic leukemia

New England Journal of Medicine

Volumn 337, Issue 15, 1997, Pages 1021-1028

  Tallman, Martin S ^a   Andersen, Janet W ^b   Schiffer, Charles A ^c   Appelbaum, Frederick R ^d   Feusner, James H ^e   Ogden, Angela ^f   Shepherd, Lois ^g   Willman, Cheryl ^h   Bloomfield, Clara D ⁱ   Rowe, Jacob M ^j   Wiernik, Peter H ^k  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e CHILDREN S HOSPITAL OAKLAND   (United States)

^f TEXAS CHILDREN S CANCER CENTER   (United States)

^g Queen's Cancer Research Institute   (Canada)

^h UNIVERSITY OF NEW MEXICO   (United States)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j UNIVERSITY OF ROCHESTER   (United States)

^k MONTEFIORE MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; LEUKEMIA REMISSION; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; STOMATITIS; THROMBOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT FAILURE; TRETINOIN;

EID: 0030923479     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199710093371501     Document Type: Article

References (37)

1. Wiernik PH, Gallagher RE, Tollman MS. Diagnosis and treatment of acute promyelocytic leukemia. In: Wiernik PH, Canellos GP, Dutcher JP, Kyle RA, eds. Neoplastic diseases of the blood. 3rd ed. New York: Churchill Livingstone, 1996:353-80.
2. Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984;76:827-41.
3. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990;347:358-61.
4. Kakizuka A, Miller WH Jr, Umesono K, et al. Chromosome translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991;66:663-74.
5. Miller WH Jr, Warrell RP Jr, Frankel SR, et al. Novel retinoic acid receptor-alpha transcripts in acute promyelocytic leukemia responsive to all-trans-retinoic acid. J Natl Cancer Inst 1990;82:1932-3.
6. Longo L, Pandolfi PP, Biondi A, et al. Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. J Exp Med 1990;172:1571-5.
7. Cordonnier C, Vernant JP, Brun B, et al. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985;55:18-25.
8. Kantarjian HM, Keating MJ, Walters RS, et al. Acute promyelocytic leukemia: M.D. Anderson Hospital experience. Am J Med 1986;80:789-97.
9. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992;79:543-53.
10. Chomienne C, Ballerini P, Balitrand N, et al. All-trans retinoic acid in acute promyelocytic leukemia. II. In vitro studies: structure-function relationship. Blood 1990;76:1710-7.
11. Elliott S, Taylor K, White S, et al. Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis. Blood 1992;79:1916-9.
12. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-72.
13. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;76:1704-9.
14. Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991;324:1385-93.
15. Chen ZX, Xue YQ, Zhang R, et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991;78:1413-9.
16. Fenaux P, Castaigne S, Dombret H, et al. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992;80:2176-81.
17. Ohno R, Yoshida H, Fukutani H, et al. Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 1993;7:1722-7.
18. Frankel SR, Eardley A, Heller G, et al. All-trans retinoic acid for acute promyelocytic leukemia: results of the New York Study. Ann Intern Med 1994;120:278-86.
19. Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995;85:1202-6.
20. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813-9.
21. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 1992;117:292-6.
22. Mehta CR, Patel NR, Tsiatis AA. Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics 1984;40: 819-25.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
24. Gallagher RE, Willman CL, Slack JL, et al. Association of PML-RARα type with pre-treatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood 1997;90:1656-63.
25. Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial: European APL 91 Group. Blood 1993;82:3241-9.
26. Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 1989;73:1116-22.
27. Bennett JM, Andersen JW, Cassileth PA. Long term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group (ECOG) experience. Leuk Res 1991;15:223-7.
28. Wiley JS, Firkin FC. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Leukemia 1995;9:774-8.
29. Chen GQ, Shen ZX, Wu F, et al. Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Leukemia 1996;10:825-8.
30. Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996;88:1390-8.
31. Head D, Kopecky KJ, Weick J, et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 1995;86:1717-28.
32. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997;15:483-90.
33. Miller WH Jr, Kakizuka A, Frankel SR, et al. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1992;89:2694-8.
34. Lo Coco F, Diverio D, Pandolfi PP, et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992;340:1437-8.
35. Korninger L, Knobl P, Laczika K, et al. PML-RAR alpha PCR positivity in the bone marrow of patients with APL precedes haematological relapse by 2-3 months. Br J Haematol 1994;88:427-31.
36. Eardley AM, Heller G, Warrell RP Jr. Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia. Leukemia 1994;8:934-9.
37. Takeshita A, Sakamaki H, Miyawaki S, et al. Significant reduction in medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. Cancer 1995;76:602-8.